Diphtheria?

Historical Treatment and Serum Therapy

Émile Roux and colleagues developed diphtheria antitoxin in the 1890s, isolating serum from horses immunized against diphtheria toxin. The antitoxin neutralizes the circulating toxin but does not kill the bacterium itself. This distinction became the structural problem of twentieth-century medicine: the disease could be arrested by passive immunization, but the infection could not be eliminated. By the early twentieth century, diphtheria antitoxin was the only systemic treatment for any bacterial toxin-mediated disease. It remained the only such treatment throughout this timeline.

The initial hope—that early injection of antitoxin might prevent both toxin damage and ongoing bacterial growth—proved unfounded. Clinical outcomes depended entirely on the speed and quantity of antitoxin given, but even early, aggressive dosing merely stopped the toxin's effects. The bacterium persisted in the throat until the patient's own immune response cleared it or the disease progressed to secondary pneumonia, septicaemia, or endocarditis. Mortality in the 1920s-30s from antitoxin-treated diphtheria remained between 5 and 15 percent depending on patient age, dose timing, and bacterial strain sensitivity to the limited azo drugs available for local throat treatment.

The Halloway-Umezaki method, developed in the 1970s as a refined serum therapy protocol, offered improved survival rates through larger hyperimmune doses and better timing protocols. Dorothy Umezaki and colleagues demonstrated that early antitoxin combined with improved supportive care and isolation could reduce mortality to 2-3 percent in developed-world settings. Yet the underlying mechanism—toxin neutralization rather than bacterial elimination—remained unchanged.

Epidemiology and Prevention

After the Bacillary Congress of Geneva in 1952 formalized asepsis maximalism doctrine, diphtheria prevention shifted decisively toward immunization rather than treatment. Mass vaccination with diphtheria toxoid (inactivated toxin) became the coordinated public health strategy across industrial nations. Where vaccination coverage reached 85 percent or higher, the disease became rare enough that most medical students never encountered it clinically. In populations with lower vaccination rates, diphtheria remained a leading cause of childhood death into the 1960s.

The Geneva Sanitary Bureau's records show diphtheria incidence in vaccinated populations fell from approximately 50 cases per 100,000 children in 1950 to fewer than 1 per 100,000 by 1980 in fully compliant nations. However, unvaccinated populations and regions with interrupted immunization programs experienced regular outbreaks. A significant outbreak in the Soviet Union in 1990-1998, affecting over 100,000 people, demonstrated the disease's persistence as an immediate threat in any population that lapsed from vaccination discipline.

Clinical Significance

Social and Occupational Dimensions